Place of Origin: | China |
---|---|
Brand Name: | HNB |
Certification: | ISO |
Model Number: | Bremelanotide PT 141 |
Minimum Order Quantity: | 1KG |
Price: | Negotiable |
Packaging Details: | Aluminum foil bag |
Delivery Time: | Usually3-5days |
Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram,Alibaba Assurance Order |
Supply Ability: | 5000kg/Month |
CAS: | 189691-06-3 | Mf: | C50H68N14O10 |
---|---|---|---|
MW: | 1025.16 | Specification: | 99% |
Einecs No.: | N/A | Appearance: | White Crystalline Powder |
Sample: | Available | Whatsapp: | +86 15202961574 |
High Light: | Bremelanotide Sexual Enhancement Powder,PT 141 Bremelanotide Polypeptide,PT 141 Peptide Increase Female Libido |
polypeptide Increase female libido PT 141 Bremelanotide
Product name |
BREMELANOTIDE PT 141 |
Appearance |
White Crystalline Powder |
CAS |
189691-06-3 |
MF |
C50H68N14O10 |
Purity |
99% |
Storage |
Keep in cool dry place. |
whatsapp: +86 15202961574
The Introductction of BREMELANOTIDE PT 141
PT141, also known as Bremelanotide, is a drug used to treat female sel dysfunction. PT-141 has shown positive Chemicalbook results in a phase I clinical trial administered to normal premenopausal women. It helps premenopausal women with hypoactive libido to maintain a normal sel desire.
Bremelanotide PT141 is an MC4R agonist and a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH), a cyclic peptide derivative of melanocortin containing 7 amino acids, which regulates the pathways involved in the sel response in the brain. It has been shown to have pharmacological effects and safety in the treatment of se dysfunction.
The Application & Function of BREMELANOTIDE PT 141
Bremelanotide PT141 has pharmacological effects and safety in the treatment of sel dysfunction
Bremelanotide PT141 subcutaneous injection is indicated for the treatment of acquired, broadly defined HSDD in premenopausal women characterized by a low sel desire that causes significant psychological distress or interpersonal difficulties, and is not due to a concurrent medical or psychiatric illness, relationship problems, or the use of therapeutic medications or drugs that cause euphoric, hallucinogenic, narcotic, or dependence effects. Acquired HSDD is HSDD that occurs in patients who have not previously had problems with se desire. broad HSDD is HSDD that occurs regardless of the type of stimulation, situation, or partner. bumetanide subcutaneous injection is not indicated for the treatment of hypogonadism in postmenopausal women or men and is not intended to enhance sel behavior.
Other Name of BREMELANOTIDE PT 141: Bremerdam;REMELANOTIDE;Brmelanotice;BREMELANOTIDE;PT-141 USP/EP/BP;Pt-141, Bremerdam;BREMELANOTIDE PT141;Bremelanotide See B677355;Bremelanotide, PT141,PT-141;Bremelanotide,α-MSH (PT-141);N -acetyl- L -norleucyl- L -aspartyl- L -histidyl- D -phenylalanyl- L -arginyl- L -tryptophyl- L -lysine C-4.2-N-6,7-lactam
The COA of BREMELANOTIDE PT 141